Nilotinib therapy in chronic myelogenous leukemia

Alfonso Quintás-Cardama, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

Imatinib mesylate (Gleevec®; Novartis, Basel, Switzerland) is a highly effective inhibitor of the deregulated kinase activity of BCR-ABL in chronic myelogenous leukemia (CML) and represents the current standard of care for patients with this disease. Mutations within the ABL kinase domain that interfere with drug binding have been identified as the main mechanism of resistance to imatinib. Currently, more than 50 different BCR-ABL mutants conferring varying degrees of resistance to tyrosine kinase inhibitors have been identified. Nilotinib (Tasigna®; Novartis) is a second-generation tyrosine kinase inhibitor with 30-fold higher potency against BCR-ABL kinase than imatinib. Notably, nilotinib is active against a wide range of imatinib-resistant or-intolerant patients, except for T315I. Results from the pivotal phase II studies of nilotinib for patients with CML after failure or intolerance to imatinib therapy indicate that nilotinib has a favorable toxicity profile and is highly efficacious in this setting. Studies exploring the efficacy of nilotinib as front-line therapy for patients with newly diagnosed CML are ongoing. Here, we review the preclinical and clinical development of nilotinib for the treatment of CML.

Original languageEnglish (US)
Pages (from-to)691-702
Number of pages12
JournalDrugs of Today
Volume43
Issue number10
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phosphotransferases
Protein-Tyrosine Kinases
Therapeutics
Standard of Care
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Switzerland
Imatinib Mesylate
Mutation
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Nilotinib therapy in chronic myelogenous leukemia. / Quintás-Cardama, Alfonso; Cortes, Jorge.

In: Drugs of Today, Vol. 43, No. 10, 01.10.2007, p. 691-702.

Research output: Contribution to journalReview article

Quintás-Cardama, Alfonso ; Cortes, Jorge. / Nilotinib therapy in chronic myelogenous leukemia. In: Drugs of Today. 2007 ; Vol. 43, No. 10. pp. 691-702.
@article{93d1b62a022f45edb6e260a3867de5cd,
title = "Nilotinib therapy in chronic myelogenous leukemia",
abstract = "Imatinib mesylate (Gleevec{\circledR}; Novartis, Basel, Switzerland) is a highly effective inhibitor of the deregulated kinase activity of BCR-ABL in chronic myelogenous leukemia (CML) and represents the current standard of care for patients with this disease. Mutations within the ABL kinase domain that interfere with drug binding have been identified as the main mechanism of resistance to imatinib. Currently, more than 50 different BCR-ABL mutants conferring varying degrees of resistance to tyrosine kinase inhibitors have been identified. Nilotinib (Tasigna{\circledR}; Novartis) is a second-generation tyrosine kinase inhibitor with 30-fold higher potency against BCR-ABL kinase than imatinib. Notably, nilotinib is active against a wide range of imatinib-resistant or-intolerant patients, except for T315I. Results from the pivotal phase II studies of nilotinib for patients with CML after failure or intolerance to imatinib therapy indicate that nilotinib has a favorable toxicity profile and is highly efficacious in this setting. Studies exploring the efficacy of nilotinib as front-line therapy for patients with newly diagnosed CML are ongoing. Here, we review the preclinical and clinical development of nilotinib for the treatment of CML.",
author = "Alfonso Quint{\'a}s-Cardama and Jorge Cortes",
year = "2007",
month = "10",
day = "1",
doi = "10.1358/dot.2007.43.10.1122218",
language = "English (US)",
volume = "43",
pages = "691--702",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "10",

}

TY - JOUR

T1 - Nilotinib therapy in chronic myelogenous leukemia

AU - Quintás-Cardama, Alfonso

AU - Cortes, Jorge

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Imatinib mesylate (Gleevec®; Novartis, Basel, Switzerland) is a highly effective inhibitor of the deregulated kinase activity of BCR-ABL in chronic myelogenous leukemia (CML) and represents the current standard of care for patients with this disease. Mutations within the ABL kinase domain that interfere with drug binding have been identified as the main mechanism of resistance to imatinib. Currently, more than 50 different BCR-ABL mutants conferring varying degrees of resistance to tyrosine kinase inhibitors have been identified. Nilotinib (Tasigna®; Novartis) is a second-generation tyrosine kinase inhibitor with 30-fold higher potency against BCR-ABL kinase than imatinib. Notably, nilotinib is active against a wide range of imatinib-resistant or-intolerant patients, except for T315I. Results from the pivotal phase II studies of nilotinib for patients with CML after failure or intolerance to imatinib therapy indicate that nilotinib has a favorable toxicity profile and is highly efficacious in this setting. Studies exploring the efficacy of nilotinib as front-line therapy for patients with newly diagnosed CML are ongoing. Here, we review the preclinical and clinical development of nilotinib for the treatment of CML.

AB - Imatinib mesylate (Gleevec®; Novartis, Basel, Switzerland) is a highly effective inhibitor of the deregulated kinase activity of BCR-ABL in chronic myelogenous leukemia (CML) and represents the current standard of care for patients with this disease. Mutations within the ABL kinase domain that interfere with drug binding have been identified as the main mechanism of resistance to imatinib. Currently, more than 50 different BCR-ABL mutants conferring varying degrees of resistance to tyrosine kinase inhibitors have been identified. Nilotinib (Tasigna®; Novartis) is a second-generation tyrosine kinase inhibitor with 30-fold higher potency against BCR-ABL kinase than imatinib. Notably, nilotinib is active against a wide range of imatinib-resistant or-intolerant patients, except for T315I. Results from the pivotal phase II studies of nilotinib for patients with CML after failure or intolerance to imatinib therapy indicate that nilotinib has a favorable toxicity profile and is highly efficacious in this setting. Studies exploring the efficacy of nilotinib as front-line therapy for patients with newly diagnosed CML are ongoing. Here, we review the preclinical and clinical development of nilotinib for the treatment of CML.

UR - http://www.scopus.com/inward/record.url?scp=36849002849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849002849&partnerID=8YFLogxK

U2 - 10.1358/dot.2007.43.10.1122218

DO - 10.1358/dot.2007.43.10.1122218

M3 - Review article

C2 - 17987222

AN - SCOPUS:36849002849

VL - 43

SP - 691

EP - 702

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 10

ER -